TY - JOUR
T1 - St-segment resolution and infarct-related artery patency and flow after thrombolytic therapy
AU - de Lemos, James A
AU - Antman, Elliott M.
AU - Giugliano, Robert P.
AU - McCabe, Carolyn H.
AU - Murphy, Sabina A.
AU - Van De Werf, Frans
AU - Gibson, C. Michael
AU - Braunwald, Eugene
N1 - Funding Information:
This study was supported by a grant from Centocor, Malvern, Pennsylvania, and Eli Lilly, Inc., Indianapolis, Indiana.
Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000/2/1
Y1 - 2000/2/1
N2 - Because patients who fail to achieve reperfusion after thrombolytic therapy remain at high risk for morbidity and mortality, noninvasive measures of infarct-related artery (IRA) patency are needed to identify candidates for rescue interventions. We prospectively studied 444 patients from the Thrombolysis In Myocardial Infarction (TIMI) 14 trial with interpretable baseline and 90 minute 12-lead electrocardiograms. The percent resolution of ST-segment deviation from baseline to 90 minutes was compared with 90-minute IRA TIMI flow grade, as determined in an angiographic core laboratory. Patients with complete (≥70%) ST resolution (n = 208; 47%) had a patency (TIMI 2 or 3 flow) rate of 94%, a TIMI 3 flow rate of 79%, and a 30-day mortality rate of 1.0%. Patients with partial (30% to 70%) or no (≤30%) ST resolution had significantly lower rates of patency (72% and 68%; p <0.0001 vs complete ST resolution) and TIMI 3 flow (50% and 44%; p <0.0001 vs complete ST resolution), and higher 30-day mortality (4.2% and 5.9%; p = 0.01 vs complete ST resolution). With use of electrocardiographic criteria alone, approximately 50% of patients can be classified as having a high (94%) probability of IRA patency and a very low risk for mortality. Angiography to determine patency of the IRA may be unnecessary in these patients. In patients without complete (≥70%) ST resolution, the IRA is still likely to be patent, and additional information from clinical variables or serum markers may help to identify candidates for coronary angiography. Patients with persistent ST elevation despite a patent IRA are at increased risk for mortality, likely due to extensive microvascular and tissue injury. Copyright (C) 2000 Excerpta Medica Inc.
AB - Because patients who fail to achieve reperfusion after thrombolytic therapy remain at high risk for morbidity and mortality, noninvasive measures of infarct-related artery (IRA) patency are needed to identify candidates for rescue interventions. We prospectively studied 444 patients from the Thrombolysis In Myocardial Infarction (TIMI) 14 trial with interpretable baseline and 90 minute 12-lead electrocardiograms. The percent resolution of ST-segment deviation from baseline to 90 minutes was compared with 90-minute IRA TIMI flow grade, as determined in an angiographic core laboratory. Patients with complete (≥70%) ST resolution (n = 208; 47%) had a patency (TIMI 2 or 3 flow) rate of 94%, a TIMI 3 flow rate of 79%, and a 30-day mortality rate of 1.0%. Patients with partial (30% to 70%) or no (≤30%) ST resolution had significantly lower rates of patency (72% and 68%; p <0.0001 vs complete ST resolution) and TIMI 3 flow (50% and 44%; p <0.0001 vs complete ST resolution), and higher 30-day mortality (4.2% and 5.9%; p = 0.01 vs complete ST resolution). With use of electrocardiographic criteria alone, approximately 50% of patients can be classified as having a high (94%) probability of IRA patency and a very low risk for mortality. Angiography to determine patency of the IRA may be unnecessary in these patients. In patients without complete (≥70%) ST resolution, the IRA is still likely to be patent, and additional information from clinical variables or serum markers may help to identify candidates for coronary angiography. Patients with persistent ST elevation despite a patent IRA are at increased risk for mortality, likely due to extensive microvascular and tissue injury. Copyright (C) 2000 Excerpta Medica Inc.
UR - http://www.scopus.com/inward/record.url?scp=0033969335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033969335&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(99)00736-5
DO - 10.1016/S0002-9149(99)00736-5
M3 - Article
C2 - 11078296
AN - SCOPUS:0033969335
SN - 0002-9149
VL - 85
SP - 299
EP - 304
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3
ER -